Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

Iovance Biotherapeutics (NASDAQ:IOVA) reported updated data from its registrational IOV-LUN-202 trial of lifileucel in previously treated, non-squamous metastatic non-small cell lung cancer, outlining...

Iovance’s Lifileucel Shows 25% Lung Cancer Response Rate, Targets 2027 FDA Filing ↗

Today 13:01 EDT

Via MarketBeat

Performance

52-Week Range 37.5% below 52-week high

9.600

1.7652W Low 15.3752W High

1 Week 35.6% below 1-week high

13.321W Low 14.911W High

Iovance Biotherapeutics, Inc. - Common Stock (IOVA) traded between $1.76 and $15.37 over the past 52 weeks and last traded at $9.60, 37.5% below its 52-week high. Over the past week it ranged between $13.32 and $14.91.

Past 12 Months

-32.1%

-12.6%

+110.5%

+190.0%

+281.0%

+338.4%

1W -$4.54

1M -$1.39

3M +$5.04

6M +$6.29

YTD +$7.08

1Y +$7.41

IOVA was +338.4% over the past year, +190.0% over six months, +281.0% year to date, -32.1% in the last week.

12 Months vs Market

IOVA

+338.4%

DIA

+9.3%

SPY

+11.7%

QQQ

+12.7%

IWM

+13.9%

Over the past 12 months IOVA returned +338.4% versus DIA (Dow) +9.3%, SPY (S&P 500) +11.7%, QQQ (Nasdaq 100) +12.7% and IWM (Russell 2000) +13.9%.

Volume & Liquidity 2.75× 3-mo avg

Today 44,669,261 3-mo avg 16.3M

8.8M

15.3M

16.3M

15.8M

YTD

15.5M

IOVA most recently traded 44,669,261 shares against a 3-month average daily volume of 16.3M.

More News

Premarket Gainers and Losers on Oct. 29, 2026 ↗

Today 9:30 EDT

Via Chartmill

Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)

Today 7:00 EDT

Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy

October 28, 2026

Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026

October 27, 2026

Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026

Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market

October 26, 2026

Via FinancialNewsMedia

October 26, 2026

Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma

October 23, 2026

Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026

October 19, 2026

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

October 16, 2026

Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

October 01, 2026

Top movers analysis one hour before the close of the markets on 2026-09-29: top gainers and losers in today's session. ↗

September 29, 2026

Via Chartmill

Most active stocks in Tuesday's session ↗

September 29, 2026

Via Chartmill

These stocks are moving in today's session ↗

September 29, 2026

Via Chartmill

Traders are paying attention to the gapping stocks in Tuesday's session. ↗

September 29, 2026

Via Chartmill

Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million

September 29, 2026

Why Iovance Biotherapeutics Stock Was on Fire Today ↗

September 24, 2026

Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains ↗

September 19, 2026

Via MarketBeat

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

September 18, 2026

Iovance Biotherapeutics to Present at Upcoming Conferences

September 04, 2026

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

August 21, 2026

Iovance (IOVA) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher? ↗

August 10, 2026